SAINT® vs VNS for Treatment-Resistant Depression

If you are comparing SAINT® and VNS, you are comparing two device-based treatments for treatment-resistant depression — depression that has not improved enough after trying antidepressant medication. Both are intended for people who have not found enough relief from medication alone, but they work through entirely different mechanisms and involve very different levels of invasiveness.

SAINT® (Stanford Accelerated Intelligent Neuromodulation Therapy) is delivered on the Magnus Medical SAINT Neuromodulation System. It uses a functional MRI (fMRI) scan to personalize the treatment target for each person, then delivers 10 sessions per day over 5 consecutive days — about 50 sessions total. It is non-invasive: a coil placed on the scalp delivers magnetic pulses, with no surgery, no anesthesia, and no implanted device. It is FDA-cleared for major depressive disorder (MDD) in adults whose depression has not improved enough on prior antidepressant medication. Neuro Wellness treats adults 22 and older.

VNS (vagus nerve stimulation) involves surgically implanting a pulse generator — similar to a pacemaker — under the skin of the chest, with a lead wire connected to the left vagus nerve in the neck. The device delivers electrical pulses to the vagus nerve continuously, 24 hours a day. It is FDA-approved as an adjunctive (add-on) long-term treatment for chronic or recurrent depression in adults who have not responded to at least four antidepressant medications.

Both are legitimate treatment options. The question is which fits your diagnosis, how many medications you have already tried, and whether you are comfortable with surgery and an implanted device. Learn more about SAINT® and take the free candidacy screener to see which may apply to you.

Vagus nerve stimulation (VNS) uses a surgically implanted device to deliver electrical pulses to the vagus nerve — a long nerve that runs from the brainstem through the neck to the chest and abdomen. The device consists of a pulse generator implanted under the skin near the collarbone and a lead wire wrapped around the left vagus nerve in the neck. The generator is programmed by a clinician to deliver pulses at a set intensity and frequency, typically on for 30 seconds and off for 5 minutes, around the clock.

The FDA approved the VNS Therapy System (premarket approval application P970003) in July 2005 as an adjunctive long-term treatment for chronic or recurrent depression in adults. Specifically, the FDA indication covers adults with a depressive episode that has not responded to at least four adequate antidepressant medication trials. VNS is the only implanted device with an FDA depression indication.

VNS is not a quick treatment. Clinical studies have shown that response may take several months to appear after implantation, and the device stays in place long-term to maintain any benefit. The treatment is designed to be ongoing — the pulses continue day and night for as long as the device is active.

SAINT®, by contrast, is FDA-cleared as a complete system under 510(k) clearance K220177, with a Breakthrough Device designation. It is non-invasive, delivered as a discrete 5-day course, and does not involve surgery or an implanted device. For more on what treatment-resistant depression means, see our treatment-resistant depression guide.

The evidence base for SAINT® and VNS differs in design and the type of data available. SAINT® has published randomized controlled trial (RCT) data for the SAINT® protocol on the Magnus system. VNS has long-term observational data from registries and a randomized sham-controlled trial, but the acute response was slower and the evidence base is built around long-term follow-up rather than rapid remission.

In the 2022 randomized trial, 79% of participants reached remission (Cole et al., Am J Psychiatry 2022;179(2):132–141). Individual results may vary. That figure comes from the SAINT® trial and applies to the SAINT® protocol on the Magnus system — it does not transfer to VNS, standard TMS, or any other treatment.

VNS studies have reported response rates that increase over time. In a randomized controlled trial comparing active VNS to a sham (inactive device), response rates at 12 months were higher in the active VNS group, though the difference took months to emerge. Long-term registry data has suggested sustained benefit for some patients over several years. However, VNS is generally considered a treatment that may help over the long term rather than one that produces rapid remission.

For a deeper look at SAINT® remission and response data, see our SAINT® TMS success rates page.

The most significant difference between SAINT® and VNS is invasiveness. SAINT® is entirely non-invasive — the patient sits in a chair while a coil on the scalp delivers magnetic pulses. There is no surgery, no anesthesia, no hospital stay, and no implanted device. VNS requires surgery under anesthesia to implant a pulse generator under the skin of the chest and a lead wire around the vagus nerve in the neck. The device remains in the body and delivers pulses continuously.

On time: SAINT® compresses the entire course into 5 consecutive days, with 10 sessions per day. You are in the clinic for most of the day during treatment week, but the course is over in one week. VNS involves surgery followed by an indefinite period of ongoing stimulation. Benefit from VNS may not appear for several months, and the device stays active to maintain any improvement.

On cost: SAINT® at Neuro Wellness starts at $25,000. That price reflects the fMRI scan, the FDA-cleared targeting software, the Magnus system, physician oversight, and the full 50-session week. SAINT® may be covered by insurance; coverage varies by plan. We verify your benefits for free, whatever carrier you have, so you know what your plan allows before you commit. Financing is available for SAINT® on a case-by-case basis and is discussed during your consultation.

VNS involves surgical costs, the cost of the implanted device, and ongoing programming visits. VNS may be covered by some insurance plans, including Medicare, which has established coverage for VNS therapy for treatment-resistant depression under certain conditions. Coverage varies by plan and typically requires documentation of prior antidepressant trials. Neuro Wellness does not offer VNS. For the full SAINT® cost breakdown, see our SAINT® TMS cost page. To check what your plan covers, start with a free benefits verification.

SAINT® fits adults with major depressive disorder whose depression has not improved enough on prior antidepressant medication and who can commit to 5 consecutive days in the clinic. The compressed schedule suits people who want to avoid surgery and an implanted device, and who want a protocol with fMRI-guided personalized targeting and published randomized trial data. It is not for people with non-removable magnetic-sensitive metal near the head, certain implanted devices, or increased intracranial pressure.

VNS may be appropriate for adults with chronic or recurrent depression who have not responded to at least four antidepressant medications and who are willing to undergo surgery and carry an implanted device long-term. Because VNS is designed as an ongoing, long-term treatment, it suits someone who is comfortable with a device in their body and who understands that benefit may take months to appear.

An important consideration: VNS involves an implanted device with a lead wire near the vagus nerve. SAINT® uses magnetic pulses and is contraindicated for people with certain implanted devices or magnetic-sensitive metal. If you already have a VNS device, that may affect whether SAINT® is an option for you — this is a clinical decision that depends on the specific device and your anatomy.

Neuro Wellness offers SAINT® and standard TMS, along with SPRAVATO® (esketamine), IV ketamine, psychotherapy, and medication management. We do not offer VNS. A free consultation is the best way to learn which fits your diagnosis and circumstances. For more comparisons, see our guides to SAINT® vs ECT, SAINT® vs deep TMS, and SAINT® TMS success rates.